CrownBio Acquires Patient-derived Breast Cancer Mouse Models from University of Utah

CrownBio Acquires Patient-derived Breast Cancer Mouse Models from University of Utah
CrownBio has established an agreement with the University of Utah to acquire and commercialize the university’s unique collection of patient-derived mouse models of breast cancer. The models were developed by Alana Welm, PhD, a cancer researcher at Huntsman Cancer Institute and an associate professor in the department of Oncological Sciences at the University of Utah. With these well-characterized patient-derived xenograft (PDX) models — mice implanted with tissue or cells from a patient's tumor — Welm set out to re-create the microenvironment and underlying mechanisms of human breast cancer development, as well as its process of spreading through the body (metastasis). Because of the variability and complexity of breast cancer, it has been difficult for the scientific community to develop reliable and translatable preclinical models of the disease. To date, PDX models have been the best at mimicking the variability found in cancer patients and predicting how a treatment will perform before entering into costly clinical trials. These preclinical PDX mice include models of triple negative breast cancer, treatment-resistant cancers, and cancers with clinically relevant genetic mutations, including BRCA1 and ESR1. Crown Bioscience will make these breast cancer models accessible to the scientific community, to help improve the preclinical development o
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.